DR-01 / Dren Bio - LARVOL DELTA

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Dren Bio | N=60 ➔ 80

Enrollment change • Alopecia • Dermatology • Immunology • Vitiligo

A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Dren Bio | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (clinicaltrials.gov) - P1/2 | N=69 | Recruiting | Sponsor: Dren Bio | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A Study of Subcutaneous DR-01 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Dren Bio

New P1 trial

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization (ASH 2024) - P1/2 | "An encouraging response rate including 3 durable CRs points to the potential for DR-01 as a viable treatment option for CTL. Study DR-01-ONC-001 is currently enrolling an international cohort of patients with CTL into phase 2, part B2 of the trial."

Clinical • P1 data • Bone Marrow Transplantation • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Oncology • Pain • CD8 • KLRD1

City of Hope Reveals New Data on Cancer Immunotherapies, Microbiome and Other Innovative Topics at 2024 American Society of Hematology (ASH) Annual Meeting (Businesswire) - "City of Hope....announced today that its doctors and scientists will take part in 100 oral and poster presentations, scientific symposia/workshops, education programs and other events at ASH annual meeting from Dec. 7 to 10 in San Diego."

Clinical data

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Dren Bio | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology • Vitiligo

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Dren Bio

New P1 trial • Alopecia • Dermatology • Immunology • Vitiligo

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia (ASH 2022) - "In addition, treatments are limited to standard immunosuppressive therapy such as methotrexate, cyclosporine or cyclophosphamide, with complete response rates of only 50% or less for each agent. Additional profiling and evaluation of DR-01 in LGLL patient samples ex vivo as part of a pre-phase I study is ongoing. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients."

Preclinical • Anemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Thrombocytopenia • B3GAT1 • CD8 • FCGR3A • KLRC1 • LAMP1 • PTPRC

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas (clinicaltrials.gov) - P1/2 | N=69 | Recruiting | Sponsor: Dren Bio

New P1/2 trial • Cutaneous T-cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma